Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 3

Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

, , , ,

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    Now Viewing
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Dr Cohen:ZL-IRIAN study (NCT05229003; Wang C, et al. ASCO 2024. Abstract 3570)– Irinotecan plus anlotinib ± penpulimab in 2L mCRC
    2. Dr Ciombor: Ph II study (Zhao W, et al. ASCO 2024. Abstract 3571) – fruquintinib plus investigator choice of chemotherapy in 2L mCRC

    x